2026-05-04T15:00:30.696Z / 美国有线电视新闻网（CNN）
最高法院暂时恢复米非司酮堕胎药的邮寄与远程医疗获取渠道
作者：约翰·弗里茨
更新于13分钟前
更新时间：2026年5月4日美国东部时间上午11:17
发布时间：2026年5月4日美国东部时间上午11:00
2023年4月20日，一名患者在伊利诺伊州卡本代尔的阿拉莫妇女诊所准备服用米非司酮。
伊芙琳·霍克斯坦/路透社
美国最高法院周一暂时恢复了堕胎药米非司酮的远程医疗与邮寄渠道，回应了一项紧急上诉请求——该警告称，此前已预约获取该药物的患者可能陷入混乱。
此次“行政暂缓令”并非最终判决，仅能维持数天现状，以便法院审查该药制造商及仿制药制造商周六提交的紧急上诉。该命令暂停了美国第五巡回上诉法院的一项裁决，该裁决恢复了全美范围内要求患者当面获取该药物的规定，这一规定削弱了自最高法院推翻罗伊诉韦德案后愈发普及的药物流产渠道的可及性。
大法官塞缪尔·阿利托下达的暂停第五巡回法院裁决的命令将持续至5月11日，阿利托要求各方于周四前提交相关案件的回应意见。
相关报道：什么是米非司酮？ 阅读时长：4分钟
米非司酮生产商丹科实验室在向最高法院提交的上诉中称，第五巡回法院的命令“给高度依赖时间的医疗决策带来了即时混乱和动荡”。生产该药物仿制药的GenBioPro公司在其上诉中表示，下级法院的裁决可能“突然切断全美患者的用药渠道”。
这起快速推进的案件将该药物及堕胎议题再次带回最高法院的审理日程，距离大法官们驳回类似挑战还不到两年——当时的裁决允许该药物保持广泛可及性。阿利托负责处理来自新奥尔良的美国第五巡回上诉法院的紧急上诉案件。
自新冠疫情以来，女性可以通过远程医疗预约获取米非司酮——这是药物流产方案中的两种药物之一。拜登政府于2023年最终敲定规则，取消了患者必须当面就诊才能获取该药物的要求，这距最高法院推翻罗伊案已有一年时间。
随着保守派州响应最高法院的裁决，禁止或严格限制诊所堕胎渠道，药物流产愈发普遍。根据古特马赫研究所的研究，2023年药物流产占美国堕胎总数的60%以上。
CNN对米非司酮数据的分析显示，该药物安全性极高，报告的副作用少于伟哥或青霉素。
路易斯安那州去年提起诉讼，指控拜登政府时期的相关规定削弱了该州自身的堕胎禁令。今年4月，一家联邦地区法院拒绝在美国食品药品监督管理局完成该药物的安全性审查之前限制其获取渠道。
最高法院曾在2024年审查过这一议题，并一致驳回了一项挑战美国食品药品监督管理局监管规定的诉讼。但法院通过认定提出质疑的医生和反堕胎团体不具备起诉资格，解决了这一纠纷。这一技术性的狭义裁决意味着，未来类似挑战几乎必然会再次提交至大法官们面前。
CNN的蒂尔尼·斯奈德对本文亦有贡献。
本文已更新补充更多细节。
Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail
2026-05-04T15:00:30.696Z / CNN
Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail
By John Fritze
Updated 13 min ago
Updated May 4, 2026, 11:17 AM ET
PUBLISHED May 4, 2026, 11:00 AM ET
A patient prepares to take Mifepristone at Alamo Women’s Clinic in Carbondale, Illinois, on April 20, 2023.
Evelyn Hockstein/Reuters
The Supreme Court temporarily restored telehealth and mail access to the abortion pill mifepristone on Monday, responding to an emergency appeal that warned of potential chaos for patients who had appointments to access the drug.
The “administrative stay” is far from a final decision but rather maintains the status quo for a few days while the court reviews emergency appeals filed Saturday by the drug’s manufacturer and the maker of a generic version. The order puts on hold a decision from the conservative 5th US Circuit Court of Appeals that reinstated a nationwide requirement that the medication be obtained in person, undermining access to the method of abortion that has grown more widespread since the court overturned Roe v. Wade.
Justice Samuel Alito’s order staying the 5th Circuit ruling lasts through May 11, and Alito requested a response in the cases by Thursday.
Related article What is mifepristone? 4 min read
Danco Laboratories, the maker of mifepristone, told the Supreme Court in its appeal that the 5th Circuit order “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” GenBioPro, which makes a generic version of the drug, said in its own appeal that the lower court’s decision risked “abruptly cutting off access for patients nationwide.”
The fast-track case puts the drug and the issue of abortion back on the high court’s docket less than two years after the justices rejected a similar challenge – a decision that allowed the drug to remain widely available. Alito handles emergency appeals rising from the New Orleans-based 5th US Circuit.
Since the Covid-19 pandemic, women have been able to obtain mifepristone – one of the two drugs in the medication abortion regimen – through telehealth appointments. The Biden administration finalized rules that ended the requirement that the pills be obtained through an in-person doctor’s visit in 2023, a year after the Supreme Court overturned Roe.
As conservative states have responded to the Supreme Court’s decision by banning or severely limiting access to clinic abortions, medication abortions have become more common. Medication abortions accounted for more than 60% of abortions in the US in 2023, according to Guttmacher Institute research.
A CNN analysis of mifepristone data shows that the drug is overwhelmingly safe and has fewer reported side effects than Viagra or penicillin.
Louisiana sued last year alleging that the Biden-era regulation undermined its own abortion ban. A federal district court in April declined to restrict access to the drug until the Food and Drug Administration completed a safety review of the medication.
The Supreme Court reviewed the issue once before, in 2024, and it unanimously rejected a lawsuit challenging the FDA’s regulation. But the court resolved that dispute by concluding that the doctors and anti-abortion groups that had challenged access to the drug did not have standing to sue. That technical, narrow decision meant that future challenges were almost guaranteed to reach the justices again.
CNN’s Tierney Sneed contributed to this report.
This story has been updated with additional details.
发表回复